Literature DB >> 6211143

Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.

E D O'Donnell, E H Freimer, G L Gilardi, R Raeder.   

Abstract

N-Formimidoyl thienamycin was the most active drug against strains of Pseudomonas aeruginosa with a 90% minimum inhibitory concentration of 1.25 mug/ml. With the exception of P. maltophilia, thienamycin was as active or more active than moxalactam against other species of pseudomonads and against other genera of nonfermenters.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6211143      PMCID： PMC181966          DOI： 10.1128/AAC.21.4.673

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic.

Authors:  S S Weaver; B M LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

2.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

3.  In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.

Authors:  D G Delgado; C J Brau; C G Cobbs; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

5.  Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new).

Authors:  V L Yu; R M Vickers; J J Zuravleff
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

6.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191
View more
  6 in total

1.  In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

Authors:  R J Fass; J Barnishan; M C Solomon; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 2.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 3.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

4.  In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.

Authors:  D Henry; A G Skidmore; J Ngui-Yen; A Smith; J A Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli.

Authors:  D A Strandberg; J H Jorgensen; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  [Calculated initial chemotherapy in mechanically-ventilated postoperative patients with peritonitis, sepsis and pneumonia].

Authors:  G Hünefeld; H Weissbrodt; H Aebert; H Bunzendahl
Journal:  Infection       Date:  1986       Impact factor: 3.553
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.